SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.
Genet Med
; 23(9): 1664-1672, 2021 09.
Article
em En
| MEDLINE
| ID: mdl-34040195
ABSTRACT
PURPOSE:
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder with hypothalamic dysfunction due to deficiency of imprinted genes located on the 15q11-q13 chromosome. Among them, the SNORD116 gene appears critical for the expression of the PWS phenotype. We aimed to clarify the role of SNORD116 in cellular and animal models with regard to growth hormone therapy (GHT), the main approved treatment for PWS.METHODS:
We collected serum and induced pluripotent stem cells (iPSCs) from GH-treated PWS patients to differentiate into dopaminergic neurons, and in parallel used a Snord116 knockout mouse model. We analyzed the expression of factors potentially linked to GH responsiveness.RESULTS:
We found elevated levels of circulating IGFBP7 in naive PWS patients, with IGFBP7 levels normalizing under GHT. We found elevated IGFBP7 levels in the brains of Snord116 knockout mice and in iPSC-derived neurons from a SNORD116-deleted PWS patient. High circulating levels of IGFBP7 in PWS patients may result from both increased IGFBP7 expression and decreased IGFBP7 cleavage, by downregulation of the proconvertase PC1.CONCLUSION:
SNORD116 deletion affects IGFBP7 levels, while IGFBP7 decreases under GHT in PWS patients. Modulation of the IGFBP7 level, which interacts with IGF1, has implications in the pathophysiology and management of PWS under GHT.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Prader-Willi
/
Células-Tronco Pluripotentes Induzidas
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article